Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul 25;487(7408):482-5.
doi: 10.1038/nature11286.

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

N M Archin  1 , A L Liberty, A D Kashuba, S K Choudhary, J D Kuruc, A M Crooks, D C Parker, E M Anderson, M F Kearney, M C Strain, D D Richman, M G Hudgens, R J Bosch, J M Coffin, J J Eron, D J Hazuda, D M Margolis
Affiliations

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

N M Archin et al. Nature. .

Erratum in

  • Nature. 2012 Sep 20;489(7416):460

Abstract

Despite antiretroviral therapy, proviral latency of human immunodeficiency virus type 1 (HIV-1) remains a principal obstacle to curing the infection. Inducing the expression of latent genomes within resting CD4(+) T cells is the primary strategy to clear this reservoir. Although histone deacetylase inhibitors such as suberoylanilide hydroxamic acid (also known as vorinostat, VOR) can disrupt HIV-1 latency in vitro, the utility of this approach has never been directly proven in a translational clinical study of HIV-infected patients. Here we isolated the circulating resting CD4(+) T cells of patients in whom viraemia was fully suppressed by antiretroviral therapy, and directly studied the effect of VOR on this latent reservoir. In each of eight patients, a single dose of VOR increased both biomarkers of cellular acetylation, and simultaneously induced an increase in HIV RNA expression in resting CD4(+) cells (mean increase, 4.8-fold). This demonstrates that a molecular mechanism known to enforce HIV latency can be therapeutically targeted in humans, provides proof-of-concept for histone deacetylase inhibitors as a therapeutic class, and defines a precise approach to test novel strategies to attack and eradicate latent HIV infection directly.

Trial registration: ClinicalTrials.gov NCT01319383.

PubMed Disclaimer

Figures

Figure 1
Figure 1. The relative HIV-1 RNA copy number in resting CD4+ T cells of 13 ART-treated HIV+ patients with plasma HIV RNA BDL
Values are calculated by cycle number, and limit of quantitation of cell-associated RNA is 10 copies. Cells were cultured alone (untreated), with VOR 335 nM (VOR), or activated with 3 µg/ml PHA and 60 U/ml IL2 for 6 hours. Data from 16 patients (a), and those who later received in vivo dosing [1 (Δ), 2 (□), 3 (◊), 4 (X), 5 (▽), 6 (❍), 7 (+), and 8 (⨀)] are shown in detail (b, mean and s.d.).
Figure 1
Figure 1. The relative HIV-1 RNA copy number in resting CD4+ T cells of 13 ART-treated HIV+ patients with plasma HIV RNA BDL
Values are calculated by cycle number, and limit of quantitation of cell-associated RNA is 10 copies. Cells were cultured alone (untreated), with VOR 335 nM (VOR), or activated with 3 µg/ml PHA and 60 U/ml IL2 for 6 hours. Data from 16 patients (a), and those who later received in vivo dosing [1 (Δ), 2 (□), 3 (◊), 4 (X), 5 (▽), 6 (❍), 7 (+), and 8 (⨀)] are shown in detail (b, mean and s.d.).
Figure 2
Figure 2. VOR exposure and histone acetylation
Median VOR plasma concentrations in patients 1–8 after a single 400 mg oral dose (circles with range shown) is shown in comparison to mean total cellular acetylated histone H3 in PBMCs (diamonds with s.d. shown), and relative levels of acetylated histone H3 at the human p21 gene promoter in resting CD4+ T cells (bars, mean and s.d.). A significant increase (†) in cellular acetylated histone H3 is seen at 8 hours, p < 0.01. A trend towards increased acetylation at the p21 gene is seen in the patients (2–5, 7) in whom sufficient cells were available for analysis.
Figure 3
Figure 3. VOR upregulates HIV RNA expression
The relative HIV-1 RNA copy number (mean, s.d.) measured in the resting CD4+ T cells of eight HIV+ patients with plasma HIV RNA BDL is shown on background ART and on ART following a single 400 mg oral dose of VOR. For each subject, the differences are significant (p < 0.01).
See this image and copyright information in PMC

Comment in

  • HIV: Shock and kill.
    Deeks SG. Deeks SG. Nature. 2012 Jul 25;487(7408):439-40. doi: 10.1038/487439a. Nature. 2012. PMID: 22836995 No abstract available.
  • Viral infection: Coaxing HIV out of hiding.
    Jermy A. Jermy A. Nat Rev Microbiol. 2012 Sep;10(9):596-7. doi: 10.1038/nrmicro2861. Epub 2012 Aug 13. Nat Rev Microbiol. 2012. PMID: 22886238 No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med. 2002;53:557. - PubMed
    1. Margolis DM. Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS. 2011;6:25. - PMC - PubMed
    1. Archin NM, et al. Expression of Latent Human Immunodeficiency Type-1 is Induced by Novel and Selective Histone Deacetylase Inhibitors. AIDS. 2009;23:1799. - PMC - PubMed
    1. Archin NM, et al. Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid. AIDS Res Hum Retroviruses. 2009;25:207. - PMC - PubMed
    1. Contreras X, et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem. 2009;284:6782. - PMC - PubMed

Publication types

MeSH terms

Associated data